Mannucci P, Tuddenham E. The hemophilias—from royal genes to gene therapy. N Engl J Med. 2001;344:1773–9.

Article  CAS  PubMed  Google Scholar 

Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158.

Article  PubMed  Google Scholar 

Escobar M, Sallah S. Hemophilia A and hemophilia B: focus on arthropathy and variables affecting bleeding severity and prophylaxis. J Thromb Haemost. 2013;11(8):1449–53.

Article  CAS  PubMed  Google Scholar 

O’Hara J, Walsh S, Camp C, et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes. 2018;16(1):84.

Article  PubMed  PubMed Central  Google Scholar 

O’Hara S, Castro FA, Black J, et al. Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis. Haemophilia. 2021;27(1):113–9.

Article  PubMed  Google Scholar 

O’Hara J, Noone D, Jain M, et al. Clinical attributes and treatment characteristics are associated with work productivity and activity impairment in people with severe haemophilia A. Haemophilia. 2021;27(6):938–46.

Article  PubMed  Google Scholar 

Pastarnak A, O’Mahony B, Chai-Adisaksopha C, et al. Impact of hemophilia on employment - Insights from the PROBE Study. National Hemophilia Foundation; 2018.

Google Scholar 

Siboni SM, Mannucci PM, Gringeri A, et al. Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. J Thromb Haemost JTH. 2009;7(5):780–6.

Article  CAS  PubMed  Google Scholar 

O’Hara J, Hughes D, Camp C, et al. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Diseas. 2017;12(1):106.

Article  Google Scholar 

Berntorp E, Dolan G, Hay C, et al. European retrospective study of real-life haemophilia treatment. Haemophilia. 2017;23(1):105–14.

Article  CAS  PubMed  Google Scholar 

Manco-Johnson MJ, Soucie JM, Gill JC. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood. 2017;129(17):2368–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mannucci PM. Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A. Expert Opin Investig Drugs. 2020;29(3):303–9.

Article  CAS  PubMed  Google Scholar 

Peyvandi F, Kenet G, Pekrul I, et al. Laboratory testing in hemophilia: Impact of factor and non-factor replacement therapy on coagulation assays. J Thromb Haemost. 2020;18(6):1242–55.

Article  PubMed  Google Scholar 

Nathwani AC, Davidoff AM, Tuddenham EGD. Gene therapy for hemophilia. Hematol Oncol Clin N Am. 2017;31(5):853–68.

Article  Google Scholar 

Ferri Grazzi E, Sun SX, Burke T, et al. The impact of pharmacokinetic-guided prophylaxis on clinical outcomes and healthcare resource utilization in hemophilia a patients: real-world evidence from the CHESS II Study. JBM. 2022;13:505–16.

Article  Google Scholar 

Burke T, Asghar S, O’hara J, et al. Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe. Orphanet J Rare Dis. 2020;16:521.

Article  Google Scholar 

Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. Jo Thromb Haemost. 2014;12(11):1935–9.

Article  CAS  Google Scholar 

Burke T, Rodriguez-Santana I, Chowdary P, et al. Humanistic burden of problem joints for children and adults with haemophilia. Haemophilia. 2022;12(1):608–618.

Google Scholar 

Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol. 1993;30(3 Suppl 2):3–6.

CAS  PubMed  Google Scholar 

Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–65.

Article  CAS  PubMed  Google Scholar 

Janssen MF, Szende A, Cabases J, et al. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ. 2019;20(2):205–16.

Article  CAS  PubMed  Google Scholar 

Azzi J, Gautier L, Saba G, et al. PNS261 EQ-5D-5L in France, Germany and Spain: population norms and comparison between the countries. Value Health. 2020;23:S685.

Article  Google Scholar 

Scalone L, Cortesi PA, Ciampichini R, et al. Health related quality of life norm data of the general population in Italy: results using the EQ-5D-3L and EQ-5D-5L instruments. Epidemiol Biostat Public Health. 2015;12(3):e11457-1–e11457-15.

Google Scholar 

Grochtdreis T, Dams J, König HH, et al. Health-related quality of life measured with the EQ-5D-5L: estimation of normative index values based on a representative German population sample and value set. Eur J Health Econ. 2019;20(6):933–44.

Article  PubMed  Google Scholar 

Hernandez G, Garin O, Pardo Y, et al. Validity of the EQ-5D-5L and reference norms for the Spanish population. Qual Life Res. 2018;27(9):2337–48.

Wang M, Recht M, Iyer NN, et al. Hemophilia without prophylaxis: assessment of joint range of motion and factor activity. Res Pract Thromb Haemost. 2020;4(6):1035–45.

Article  PubMed  PubMed Central  Google Scholar 

Elander J, Robinson G, Mitchell K, et al. An assessment of the relative influence of pain coping, negative thoughts about pain, and pain acceptance on health-related quality of life among people with hemophilia. Pain. 2009;145(1):169–75.

Article  PubMed  Google Scholar 

Holstein K, Klamroth R, Richards M, et al. Pain management in patients with haemophilia: a European survey. Haemophilia. 2012;18(5):743–52.

Article  CAS  PubMed  Google Scholar 

O’Hara J, Martin AP, Nugent D, et al. Evidence of a disability paradox in patient-reported outcomes in haemophilia. Haemophilia. 2021;27(2):245–52.

Article  PubMed  PubMed Central  Google Scholar 

Limperg PF, Maurice-Stam H, Haverman L, et al. Professional functioning of young adults with congenital coagulation disorders in the Netherlands. Haemophilia. 2019;25(3):e138–45.

Article  PubMed  PubMed Central  Google Scholar 

Tundia N, Hass S, Fuldeore M, et al. Validation and US population norms of health-related productivity questionnaire. Value Health. 2015;18(3):A24.

Article  Google Scholar 

World Federation of Hemophilia. Report on the Annual Global Survey 2020. Montreal: WFH; 2021.

Google Scholar 

Rodriguez-Santana I, DasMahapatra P, Burke T, et al. Differential humanistic and economic burden of mild, moderate and severe haemophilia in european adults: a regression analysis of the CHESS II study. Orphanet J Rare Dis. 2022;17(1):1–10.

Article  Google Scholar 

Peyvandi F, Tavakkoli F, Frame D, et al. Burden of mild haemophilia A: systematic literature review. Haemophilia. 2019;25(5):755–63.

Article  PubMed  PubMed Central  Google Scholar 

Philipp C. The aging patient with hemophilia: complications, comorbidities, and management issues. Hematology Am Soc Hematol Educ Program. 2010;2010:191–6.

Article  PubMed  Google Scholar 

Trippoli S, Vaiani M, Linari S, et al. Multivariate analysis of factors influencing quality of life and utility in patients with haemophilia. Haematologica. 2001;86(7):722–8.

CAS  PubMed  Google Scholar 

Hernández Alava M, Pudney S, Wailoo A. Estimating the relationship between EQ-5D-5L and EQ-5D-